



Eric Rhodes CEO

Eric serves as the CEO of ERS Genomics. He joined ERS from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer and was responsible for commercializing Horizon's genome editing technologies as well as overseeing research and development. Over the course of his career he has held various positions focused on gene editing technologies including the positions of Director Business Development at Sigma-Aldrich and Vice President Business Development & Alliance Management at Sangamo Biosciences where he was responsible for commercializing gene-editing technologies and executed [licensing](#) deals with more than 25 major biotechnology and pharmaceutical companies. Eric holds a degree in microbiology and immunology from the University of California, Berkeley.



Michael Arciero, JD

Vice President IP & Commercial Development

Michael serves as Vice President of [Intellectual Property](#) and Corporate Development with over 15 years' experience in corporate and academic transactions. Prior to ERS, Michael served as Director of Technology Commercialization and New Ventures for the USC Stevens Center for Innovation. While there, he led the technology transfer and corporate alliance teams supporting innovation across all disciplines stemming from over \$900M in annual research expenditures. As licensing attorney for Diversa Corporation (now BASF), Michael was responsible for the negotiation and drafting of complex transactions in support of business and research development. Michael received his bachelor's degree in Biology from the University of California, San Diego and his Juris Doctorate from the University of San Diego School of law.



Ryan Donnelly received his Master's in Molecular Biotechnology, from George Washington University. He has over 10 years' experience in life sciences marketing with a heavy focus on strategic product development in both basic research & molecular diagnostics markets. At Horizon Discovery his focus is leading strategy of the research reagents portfolio consisting of Dharmacon's RNAi, gene editing, and custom oligo synthesis solutions for researchers in the life science community.

Andreas Meyer

FAS Team Member, Horizon Discovery

Andreas studied microbiology at University of Kaiserslautern, Germany and earned his PhD thesis on “plant-microbe-interactions” in the “Molecular Phytopathology” group at University of Bielefeld, Germany. Has been active in the life sciences industry since 2000 in various technical sales roles. He joined Dharmacon under Thermo Scientific in 2009 and joined Horizon Discovery 2017 with the Dharmacon acquisition. He is a member of the FAS team since 2019, covering all reagents and services including custom oligonucleotide synthesis. He specializes in gene modulation (RNAi) and CRISPR technologies, including Horizon Discovery's CRISPR services, cell line engineering and cell panel screening. He is based in Munich, Germany





Anil Chauhan  
Director ICPA

Dr. Anil Chauhan earned his Ph. D. in Genetics from the Punjab Agricultural University and MBA in International Business from Baruch college (Zicklin School of Business, New York). While at Baruch he was editorial assistant for the Policy Studies Journal - the principal outlet for the Public Policy Section of the APSA and for the PSO. Anil has worked in several companies in senior capacities including those of Vice President (Marketing), Business Head, Senior Vice President (Operations) and CEO. Anil worked with India's biotech association as its Director and Senior Advisor for almost a decade. Anil has coordinated the INDIA Pavilion at multiple International events since 2012. He organized high level panel discussions and partnering sessions at BIO Boston 2018, BIO Philadelphia 2019, Global Bio India 2019, BIO Digital USA, 2020. Global Bio India 2021. Anil recently incorporated ICPA - International Contract Pharma Association to serve the needs of contract services and solutions providers